Skip to content


  • Meeting abstract
  • Open Access

The selective enhancer substance (-)-BPAP counteracts the histological and functional consequences of an experimental stroke in rats

BMC Pharmacology20077 (Suppl 2) :A32

  • Published:


  • Ischemia
  • Protective Effect
  • Light Source
  • Cerebral Cortex
  • Tissue Damage

The effect of the newly developed, up to the present most potent and selective enhancer substance, R-(-)-1-(benzofuran-2-yl)-2-propylaminopentane [(-)-BPAP], was studied in rats exposed to an experimental stroke. Permanent focal ischemia was induced by cortical photothrombosis in Wistar rats with Rose Bengal (20 mg/kg, i.v.), irradiated by a cold light source for 10 min. Rats were treated daily with (-)-BPAP (0.2 mg/kg, i.p.) for 3 days. The infarction was visualized with 2% TTC. The lesion size was evaluated by morphometry using image analysis software (AxioVison/Zeiss). The effect of (-)-BPAP on the learning ability of rats was measured in the shuttle box. The acquisition of a two-way conditioned avoidance reflex (CAR) was analyzed during 5 consecutive days. The rats were trained with 100 trials per day. The light-irradiation for 10 min after injection of Rose Bengal caused well-demarcated tissue damage in the cerebral cortex and decreased the performance of the lesioned rats in the shuttle box. (-)-BPAP treatment caused a statistically significant reduction of the infarct size (from 1.190 ± 0.096 mm2 to 0.256 ± 0.057 mm2; n = 18) and improved the performance of the rats (45.75 ± 15 to 75.67 ± 7.2; n = 12). The data are in excellent harmony with the series of papers which described the protective effect of (-)-BPAP in various types of enhancer-sensitive cultured cells.



This work was supported by the Health Scientific Council (ETT 140/2003, ETT 606/2006).

Authors’ Affiliations

Department of Pharmacology and Pharmacotherapy, Semmelweis University, Budapest, Hungary


© Dénes and Miklya; licensee BioMed Central Ltd. 2007

This article is published under license to BioMed Central Ltd.